Sensitizing tumours to immunotherapy: Development of an RNA-based therapeutic for pancreatic adenocarcinoma that targets the immunosuppressive tumour microenvironment.

肿瘤的血管高度异常，导致微环境内的渗漏和缺氧。这些异常导致病理学和对治疗的抵抗。我们已经开发出一种新药，能够抑制血管渗漏，改善对治疗的反应，改善疾病的结果。这项工作将通过与国际制药公司的互动，为该药物的临床试验开发提供必要的数据。

The blood vessels of tumours are highly abnormal resulting in leakiness and hypoxia within the microenvironment. These abnormalities contribute both to the pathology and also to resistance to treatment. We have developed a new drug that is able to inhibit vascular leak, better the response to therapies and improve disease outcome. This work will generate essential data for the development of this drug towards Clinical Trials through interaction with International Pharma.